Rapid communication Open Access
Like 0


Increased febrile reactions in Australian children from one influenza vaccine brand in 2010 diminished confidence in influenza immunisation, highlighting the need for improved vaccine safety surveillance. , a national vaccine safety surveillance system collected adverse events in young children for 2015 influenza vaccine brands in real time through parent/carer reports via SMS/email. Weekly cumulative data on 3,340 children demonstrated low rates of fever (4.4%) and medical attendance (1.1%). Fever was more frequent with concomitant vaccination.


Article metrics loading...

Loading full text...

Full text loading...



  1. AusVaxSafety. AusVaxSafety Final report to the Australian Government Department of Health for Contract HEALTH/082/2014. Sydney: National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases; Dec 2014.
  2. Khandaker G. Going national: AusVaxSafety 2014 and beyond. Active surveillance for adverse events following immunisation - new methods in vaccine pharmacovigilance. Conference on Vaccine safety: active surveillance for adverse events following immunisation – new methods in vaccine pharmacovigilance; 29 Oct 2014; North Sydney, Australia.
  3. Hull B, Dey A, Beard F, Menzies R, Brotherton J, McIntyre P. Annual immunisation coverage report 2013. Westmead: National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases; 2013. Available from: http://ncirs.edu.au/assets/surveillance/coverage/2013-coverage-report-final.pdf
  4. Australian demographic statistics, Mar 2015. Sydney: Australian Bureau of Statistics. [Accessed: 30 September 2015]. Available from: http://www.abs.gov.au/ausstats/[email protected]/mf/3101.0
  5. Cashman P, Moberley S, Dalton C, Stephenson J, Elvidge E, Butler M, et al. Vaxtracker: Active on-line surveillance for adverse events following inactivated influenza vaccine in children. Vaccine. 2014;32(42):5503-8.  https://doi.org/10.1016/j.vaccine.2014.07.061  PMID: 25077424 
  6. Leeb A, Regan AK, Peters IJ, Leeb C, Leeb G, Effler PV. Using automated text messages to monitor adverse events following immunisation in general practice. Med J Aust. 2014;200(7):416-8.  https://doi.org/10.5694/mja13.11166  PMID: 24794676 
  7. Mahajan D, Dey A, Cook J, Harvey B, Menzies RI, Macartney KM. Surveillance of adverse events following immunisation in Australia, 2012. Commun Dis Intell Q Rep. 2014;38(3):E232-46. PMID: 25391415 
  8. Lucas J, Crosier R. Fast initial response for cusum quality-control schemes: give your cusum a head start. Technometrics. 1982;24(3):199-205.  https://doi.org/10.1080/00401706.1982.10487759 
  9. Grigg OA, Farewell VT, Spiegelhalter DJ. Use of risk-adjusted CUSUM and RSPRT charts for monitoring in medical contexts. Stat Methods Med Res. 2003;12(2):147-70. PMID: 12665208 
  10. Blyth CC, Markus TY, Effler PV, Richmond PC. Ensuring safety of the 2011 trivalent influenza vaccine in young children. Med J Aust. 2011;195(1):52. PMID: 21728948 
  11. Wood NJ, Blyth CC, Willis GA, Richmond P, Gold MS, Buttery JP, et al. The safety of seasonal influenza vaccines in Australian children in 2013. Med J Aust. 2014;201(10):596-600.  https://doi.org/10.5694/mja13.00097  PMID: 25390267 
  12. Li-Kim-Moy J, Yin JK, Rashid H, Khandaker G, King C, Wood N, et al. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children. Euro Surveill. 2015;20(24):21159.  https://doi.org/10.2807/1560-7917.ES2015.20.24.21159  PMID: 26111238 
  13. Tracey LE, Regan AK, Mak DB, Effler PV. Adverse events following influenza immunization reported by healthcare personnel using active surveillance based on text messages. Infect Control Hosp Epidemiol. 2015;36(5):608-10.  https://doi.org/10.1017/ice.2015.16  PMID: 25652211 
  14. Regan AK, Blyth CC, Mak DB, Richmond PC, Effler PV. Using SMS to monitor adverse events following trivalent influenza vaccination in pregnant women. Aust N Z J Obstet Gynaecol. 2014;54(6):522-8.  https://doi.org/10.1111/ajo.12266  PMID: 25306915 
  15. Stockwell MS, Broder K, LaRussa P, Lewis P, Fernandez N, Sharma D, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatr. 2014;168(3):211-9.  https://doi.org/10.1001/jamapediatrics.2013.4469  PMID: 24395025 
  16. Armstrong PK, Dowse GK, Effler PV, Carcione D, Blyth CC, Richmond PC, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open. 2011;1(1):e000016.  https://doi.org/10.1136/bmjopen-2010-000016  PMID: 22021725 
  17. Rockman S, Dyson A, Koernig S, Becher D, Ng M, Morelli AB, et al. Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is associated with adverse events. Vaccine. 2014;32(30):3861-8.  https://doi.org/10.1016/j.vaccine.2014.03.032  PMID: 24928062 
  18. Blyth CC, Richmond PC, Jacoby P, Thornton P, Regan A, Robins C, et al. The impact of pandemic A(H1N1)pdm09 influenza and vaccine-associated adverse events on parental attitudes and influenza vaccine uptake in young children. Vaccine. 2014;32(32):4075-81.  https://doi.org/10.1016/j.vaccine.2014.05.055  PMID: 24877764 
  19. Government of Western Australia Department of Health. Child influenza vaccination rate low despite rise in uptake. Disease WAtch. 2013;17(4). Available from: http://www.health.wa.gov.au/diseasewatch/vol17_issue4/child_vaccination.cfm

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error